Cited by

• Radiofrequency ablation combined with transcatheter arterial chemoembolization for recurrent liver cancer.

  Guo JY, Zhao LL, Cai HJ, Zeng H, Mei WD. Guo JY, et al. World J Gastrointest Surg. 2024 Jun 27;16(6):1756-1764. doi: 10.4240/wjgs.v16.i6.1756. World J Gastrointest Surg. 2024. PMID: 38983320 Free PMC article.
• Partial response of hepatocellular carcinoma to lenalidomide following progression in response to lenvatinib: A case report.

  Zhang X, Liu P, Fu Q, Luo QK, Yu PF, Chen JY, Wang YZ, Qin T. Zhang X, et al. Exp Ther Med. 2024 Jul 5;28(3):352. doi: 10.3892/etm.2024.12642. eCollection 2024 Sep. Exp Ther Med. 2024. PMID: 39071899 Free PMC article.
• Transarterial chemoembolization combined donafenib with/without PD-1 for unresectable HCC in a multicenter retrospective study.

  Li H, Wang J, Zhang G, Kuang D, Li Y, He X, Xing C, Wang Y, Shi M, Han X, Ren J, Duan X. Li H, et al. Front Immunol. 2023 Nov 27;14:1277329. doi: 10.3389/fimmu.2023.1277329. eCollection 2023. Front Immunol. 2023. PMID: 38090566 Free PMC article.
• Prognostic analysis of hepatocellular carcinoma with macrovascular invasion after liver resection and a successful case of conversion therapy.

  Ji M, Zou H, Shu B, Liu G, Zhang B, Xu Z, Pang F, Cheng M, Sun Y, Du T, Sun C, Zhu C. Ji M, et al. Front Surg. 2022 Nov 7;9:1042431. doi: 10.3389/fsurg.2022.1042431. eCollection 2022. Front Surg. 2022. PMID: 36420403 Free PMC article.
• Radiotherapy with Targeted Therapy or Immune Checkpoint Inhibitors for Hepatocellular Carcinoma with Hepatic Vein and/or Inferior Vena Cava Tumor Thrombi.

  Li Z, Zhai Y, Wu F, Cao D, Ye F, Song Y, Wang S, Liu Y, Song Y, Tang Y, Jing H, Fang H, Qi S, Lu N, Li YX, Wu J, Chen B. Li Z, et al. J Hepatocell Carcinoma. 2024 Aug 5;11:1481-1493. doi: 10.2147/JHC.S464140. eCollection 2024. J Hepatocell Carcinoma. 2024. PMID: 39131509 Free PMC article.